| [1] |
Lopci E, Fanti S. Non-FDG PET/CT[M]//Schober O, Kiessling F, Debus J. Molecular imaging in oncology. Cham: Springer, 2020: 669−718. DOI: 10.1007/978-3-030-42618-7_20. |
| [2] |
Martiniova L, De Palatis L, Etchebehere E, et al.
Gallium-68 in medical imaging[J]. Curr RadiopharmCurr Radiopharm, 2016, 9(3): 187-207.
doi: 10.2174/1874471009666161028150654 |
| [3] |
Garzón JRG, de Arcocha Torres M, Delgado-Bolton R, et al. 68Ga-PSMA PET/CT in prostate cancer[J/OL]. Rev Esp Med Nucl Imagen Mol (Engl Ed), 2018, 37(2): 130−138[2022-10-07]. https://www.sciencedirect.com/science/article/abs/pii/S2253654X17300744?via%3Dihub. DOI: 10.1016/j.remn.2017.07.004. |
| [4] |
Zhao RN, Li YJ, Nie LH, et al.
The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan[J]. Medicine (Baltimore)Medicine (Baltimore), 2021, 100(15): e25417-.
doi: 10.1097/MD.0000000000025417 |
| [5] |
Hu XW, Wu Y, Yang PQ, et al.
Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis[J]. Int Braz J UrolInt Braz J Urol, 2022, 48(6): 891-902.
doi: 10.1590/S1677-5538.IBJU.2020.0986 |
| [6] |
Sanli Y, Garg I, Kandathil A, et al.
Neuroendocrine tumor diagnosis and management: 68Ga-DOTATATE PET/CT[J]. AJR Am J RoentgenolAJR Am J Roentgenol, 2018, 211(2): 267-277.
doi: 10.2214/AJR.18.19881 |
| [7] |
Brauer G. Handbook of preparative inorganic chemistry[M]. 2nd ed. New York: Academic Press, 1963: 738. |
| [8] |
Kim SB, Song IH, Song YS, et al. Biodistribution and internal radiation dosimetry of a companion diagnostic radiopharmaceutical, [68Ga]PSMA-11, in subcutaneous prostate cancer xenograft model mice[J/OL]. Sci Rep, 2021, 11(1): 15263[2022-10-07]. https://www.nature.com/articles/s41598-021-94684-6. DOI: 10.1038/s41598-021-94684-6. |
| [9] |
冯悦, 钟萌, 罗见春, 等.
18F-FDG PET/CT技术监测雷公藤甲素对类风湿关节炎模型大鼠关节损伤的改善作用[J]. 中国药房中国药房, 2018, 29(22): 3059-3062.
doi: 10.6039/j.issn.1001-0408.2018.22.08 Feng Y, Zhong M, Luo JC, et al. Improvement effects of triptolide on joint injury in rheumatoid arthritis model rats monitored by 18F-FDG PET/CT imaging[J]. China PharmChina Pharm, 2018, 29(22): 3059-3062. doi: 10.6039/j.issn.1001-0408.2018.22.08 |
| [10] |
Hoffmann MA, Wieler HJ, Baues C, et al.
The impact of 68Ga-PSMA PET/CT and PET/MRI on the management of prostate cancer[J]. UrologyUrology, 2019, 130: 1-12.
doi: 10.1016/j.urology.2019.04.004 |
| [11] |
陈跃, 霍力, 兰晓莉, 等.
68Ga-前列腺特异性膜抗原PET/CT前列腺癌显像操作指南[J]. 中国医学影像技术中国医学影像技术, 2019, 35(10): 1441-1444.
doi: 10.13929/j.1003-3289.201905087 Chen Y, Huo L, Lan XL, et al. Guideline of 68Ga-PSMA PET/CT imaging in prostatic cancer[J]. Chin J Med Imaging TechnolChin J Med Imaging Technol, 2019, 35(10): 1441-1444. doi: 10.13929/j.1003-3289.201905087 |
| [12] |
Banerjee SR, Kumar V, Lisok A, et al.
177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2019, 46(12): 2545-2557.
doi: 10.1007/s00259-019-04434-0 |
| [13] |
Pernthaler B, Kulnik R, Gstettner C, et al.
A prospective head-to-head comparison of 18F-fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET/CT[J]. Clin Nucl MedClin Nucl Med, 2019, 44(10): e566-e573.
doi: 10.1097/RLU.0000000000002703 |
| [14] |
Giesel FL, Will L, Lawal I, et al.
Intraindividual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study[J]. J Nucl MedJ Nucl Med, 2018, 59(7): 1076-1080.
doi: 10.2967/jnumed.117.204669 |
| [15] |
Banerjee S, Pillai MRA, Knapp FF.
Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications[J]. Chem RevChem Rev, 2015, 115(8): 2934-2974.
doi: 10.1021/cr500171e |
| [16] |
Hofman MS, Violet J, Hicks RJ, et al.
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study[J]. Lancet OncolLancet Oncol, 2018, 19(6): 825-833.
doi: 10.1016/S1470-2045(18)30198-0 |
| [17] |
Fendler WP, Calais J, Eiber M, et al.
Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial[J]. JAMA OncolJAMA Oncol, 2019, 5(6): 856-863.
doi: 10.1001/jamaoncol.2019.0096 |
| [18] |
Eiber M, Maurer T, Souvatzoglou M, et al.
Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy[J]. J Nucl MedJ Nucl Med, 2015, 56(5): 668-674.
doi: 10.2967/jnumed.115.154153 |
| [19] |
Hofman MS, Lawrentschuk N, Francis RJ, et al.
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study[J]. LancetLancet, 2020, 395(10231): 1208-1216.
doi: 10.1016/S0140-6736(20)30314-7 |
| [20] |
Farolfi A, Lima GM, Oyen W, et al.
Molecular imaging and theranostics—a multidisciplinary approach[J]. Semin Nucl MedSemin Nucl Med, 2019, 49(4): 247-254.
doi: 10.1053/j.semnuclmed.2019.02.002 |